Cargando…

A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose

In recent times, new onset or relapse of nephrotic syndrome following the first dose of SARS-CoV-2 vaccines has been reported. Although the vaccination could trigger nephrotic syndrome, the question of whether the same vaccine should be administered as the second dose remains unanswered. A 25-year-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mochizuki, Reika Ikegami, Takahashi, Naohiro, Ikenouchi, Ken, Shoda, Wakana, Kuyama, Tamaki, Takahashi, Daiei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014404/
https://www.ncbi.nlm.nih.gov/pubmed/35435622
http://dx.doi.org/10.1007/s13730-022-00702-5
_version_ 1784688193937866752
author Mochizuki, Reika Ikegami
Takahashi, Naohiro
Ikenouchi, Ken
Shoda, Wakana
Kuyama, Tamaki
Takahashi, Daiei
author_facet Mochizuki, Reika Ikegami
Takahashi, Naohiro
Ikenouchi, Ken
Shoda, Wakana
Kuyama, Tamaki
Takahashi, Daiei
author_sort Mochizuki, Reika Ikegami
collection PubMed
description In recent times, new onset or relapse of nephrotic syndrome following the first dose of SARS-CoV-2 vaccines has been reported. Although the vaccination could trigger nephrotic syndrome, the question of whether the same vaccine should be administered as the second dose remains unanswered. A 25-year-old woman had taken the Moderna mRNA-1273 SARS-CoV-2 vaccine (mRNA-1273) and 26 days later, she noticed facial and peripheral edema. One week later she was referred and admitted to our hospital, wherein laboratory tests revealed that her serum creatinine level, serum albumin level, and urine protein–creatinine ratio were respectively 0.79 mg/dL, 2.5 g/dL, and 7.0 g/gCr. After a thorough inpatient examination including renal biopsy, she was diagnosed with minimal change disease (MCD) and treatment with steroids was initiated. She achieved complete remission the next day and did not experience a relapse upon receiving the second mRNA-1273 dose 56 days after the first, under treatment with 35 mg/day of oral prednisolone. This case report yields insight into determining whether patients who develop de novo MCD after the first mRNA-1273 dose should receive the second dose.
format Online
Article
Text
id pubmed-9014404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-90144042022-04-18 A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose Mochizuki, Reika Ikegami Takahashi, Naohiro Ikenouchi, Ken Shoda, Wakana Kuyama, Tamaki Takahashi, Daiei CEN Case Rep Case Report In recent times, new onset or relapse of nephrotic syndrome following the first dose of SARS-CoV-2 vaccines has been reported. Although the vaccination could trigger nephrotic syndrome, the question of whether the same vaccine should be administered as the second dose remains unanswered. A 25-year-old woman had taken the Moderna mRNA-1273 SARS-CoV-2 vaccine (mRNA-1273) and 26 days later, she noticed facial and peripheral edema. One week later she was referred and admitted to our hospital, wherein laboratory tests revealed that her serum creatinine level, serum albumin level, and urine protein–creatinine ratio were respectively 0.79 mg/dL, 2.5 g/dL, and 7.0 g/gCr. After a thorough inpatient examination including renal biopsy, she was diagnosed with minimal change disease (MCD) and treatment with steroids was initiated. She achieved complete remission the next day and did not experience a relapse upon receiving the second mRNA-1273 dose 56 days after the first, under treatment with 35 mg/day of oral prednisolone. This case report yields insight into determining whether patients who develop de novo MCD after the first mRNA-1273 dose should receive the second dose. Springer Nature Singapore 2022-04-18 /pmc/articles/PMC9014404/ /pubmed/35435622 http://dx.doi.org/10.1007/s13730-022-00702-5 Text en © The Author(s) under exclusive licence to The Japan Society of Nephrology 2022
spellingShingle Case Report
Mochizuki, Reika Ikegami
Takahashi, Naohiro
Ikenouchi, Ken
Shoda, Wakana
Kuyama, Tamaki
Takahashi, Daiei
A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title_full A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title_fullStr A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title_full_unstemmed A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title_short A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
title_sort de novo case of minimal change disease following the first dose of the moderna mrna-1273 sars-cov-2 vaccine without relapse after the second dose
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014404/
https://www.ncbi.nlm.nih.gov/pubmed/35435622
http://dx.doi.org/10.1007/s13730-022-00702-5
work_keys_str_mv AT mochizukireikaikegami adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT takahashinaohiro adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT ikenouchiken adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT shodawakana adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT kuyamatamaki adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT takahashidaiei adenovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT mochizukireikaikegami denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT takahashinaohiro denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT ikenouchiken denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT shodawakana denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT kuyamatamaki denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose
AT takahashidaiei denovocaseofminimalchangediseasefollowingthefirstdoseofthemodernamrna1273sarscov2vaccinewithoutrelapseaftertheseconddose